
Oral Solid Dosage Contract Manufacturing Market
Healthcare & Life Sciences
PDF,PPT
Reports and Insights
248
May 2022
Recent
Oral Solid Dosage Contract Manufacturing Market Overview
The report is titled as ‘Oral Solid Dosage Contract Manufacturing Market: Opportunity Analysis and Future Assessment 2022-2030’. An overview of conceptual frameworks, analytical approaches of the Oral Solid Dosage Contract Manufacturing market is the main objective of the report, which further consists the market opportunity and insights of the data involved in the making of the respective market.
The oral solid dosage contract manufacturing market is estimated to reach at a value of US$ 33.0 Bn by the end of 2022 and expected to reach at a value of US$ 49.7 Bn by 2030 with a significant CAGR of 5.3%.
Oral Solid Dosage Contract Manufacturing Introduction
The oral solid dosage refers to the term that alludes to a conclusive drug product therapy that is consumed through the mouth, dispersed in the digestive tract, and dispensed to the body via absorption into the blood flow. Some of the few examples of oral solid dosage (OSD) forms include tablets, small molecules, soft gels, capsules, gummies, effervescence, and pills. Oral solid dosage (OSD) products can be developed in various different shapes, and with those various forms comes up different production approaches and facility blueprints. Oral solid dosage has gained immense population in the present times and thus it has turned out a dominant delivery form all across the global market for majorly three grounds.
Firstly, it is comparatively simple to administer, it is simple to differentiate one oral solid dosage product from another, and lastly, the oral solid dosage manufacturing techniques are well-developed and well understood. There are contract research organizations, across the world, which are mainly outsourced companies that offer support to biotechnology and pharmaceutical companies in their clinical and preclinical analyses on the basis of an agreement.
In addition, the oral solid dosage form contract manufacturers either put forward new and innovative products or upgrade older products. The rising incidences of chronic diseases as well as soaring demand for effective treatments and therapeutics is primarily driving the growth of the global oral solid dosage contract manufacturing market over the forthcoming years.
Oral Solid Dosage Contract Manufacturing Market Segmentation
The global oral solid dosage contract manufacturing market is segmented on the basis of type, formulation, therapeutic area, dosage form, molecule type, and region.
By Type
Early Phase Development Services
Chemistry, Manufacturing & Control
Preclinical Services
Discovery Studies
Clinical Research Services
Phase I
Phase II
Phase III
Phase IV
Laboratory Services
Bioanalytical Testing
Analytical Testing
Physical Characterization
Raw Material Testing
Batch Release Testing
Stability Testing
Other Analytical Testing
Consulting Services
Data Management Services
By Formulation
Immediate Release
Sustained Release
Orally Disintegrating Tablets
By Therapeutic Area
Infectious Diseases
Neurology
CVS
Metabolic Disorders/Endocrinology
Other Therapeutic Areas
By Dosage Form
Conventional Release
Modified Release
Chewable Tablets
Effervescent Tablets
Capsules
Hard Gelatin Capsules
Soft Gelatin
Capsules/Softgels
Powders & Granules
Lozenges & Pastilles
Gummies
By Molecule Type
Small molecule API manufacturers
Biologics API Manufacturing
By Region
North America
Latin America
Europe
Asia Pacific
Middle East
Africa
Oral Solid Dosage Contract Manufacturing Market Key Players
Some of the key participating players in global oral solid dosage contract manufacturing market are:
Recipharm
Aenova Holding
Catalent
AbbVie
Patheon N.V. (Thermo Fisher Scientific)
NextPharma
Capsugel (Lonza Group AG)
Aurobindo Pharma Limited
Siegfried AG
Piramal Pharma Solutions
Corden Pharma
Kremoint Pharma Pvt Ltd.
HERMES PHARMA GmbH
Medipaams India Private Limited
Alpex Pharma
Abaris Healthcare Pvt Ltd
Ardena Holdings N.V
Aphena Pharma Solutions
Actiza Pharmaceutical Private Limited
Sunwin Healthcare PVT. LTD
Saffron Medicare PVT. LTD
Kosher Pharmaceuticals
Dr Reddy’s Lab
GlaxoSmithKline Plc
Boehringer Ingelheim
BioXcellence
Factors that are benchmarked while estimating the market
Various factors that are benchmarked while estimating the market growth includes (but not restricted to):
New product designs and launches
Current product compliance
Reimbursement
Concerns for use of Oral Solid Dosage Contract Manufacturing
Advantages of Oral Solid Dosage Contract Manufacturing
Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at regional level and in major countries globally for providing regional insights of the product segment in the report. This helps our clients to take informed decisions.
A mix of top-down and bottom-up approach is followed to arrive and validate our market value estimations. For a product segment like wherein one/two manufacturer(s) dominates the market, it’s product sales, previous growth rates and market expansion plans are considered to generate market share in the market.
Frequently Asked Question
What is the projected market size & Compound Annual Growth Rate (CAGR) of the oral solid dosage contract manufacturing market?
The oral solid dosage contract manufacturing market is estimated to reach at a value of US$ 33.0 Bn by the end of 2022 and expected to reach at a value of US$ 49.7 Bn by 2030 with a significant CAGR of 5.3%.
Which is base year calculated in the oral solid dosage contract manufacturing report?
The base year for the report is 2021 in oral solid dosage contract manufacturing market.
What segments are covered in oral solid dosage contract manufacturing market report?
The global oral solid dosage contract manufacturing market is segmented on the basis of type, formulation, therapeutic area, dosage form, molecule type, and region.
What are the key participating players in the oral solid dosage contract manufacturing market?
Recipharm, Aenova Holding, Catalent, AbbVie, Patheon N.V. (Thermo Fisher Scientific), NextPharma, Capsugel (Lonza Group AG), Aurobindo Pharma Limited, Siegfried AG, Piramal Pharma Solutions, Corden Pharma, Kremoint Pharma Pvt Ltd., HERMES PHARMA GmbH, Medipaams India Private Limited, Alpex Pharma, Abaris Healthcare Pvt Ltd, Ardena Holdings N.V, Aphena Pharma Solutions, Actiza Pharmaceutical Private Limited, Sunwin Healthcare PVT. LTD, Saffron Medicare PVT. LTD,Kosher Pharmaceuticals, Dr Reddy’s Lab, GlaxoSmithKline Plc, and Boehringer Ingelheim, BioXcellence